Companies › Myeloid Therapeutics
4 active drug programs in 4 registered trials: 4 Phase 1; Oncology, Immunology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MT-304 mRNA-LNP encoding HER2-targeted immunotherapy | ERBB2 | Phase 1 | HER2-Expressing Solid Tumors | Jan 2027 |
| MT-302 | – | Phase 1 | Epithelial Tumors, Malignant | Aug 2027 |
| MT-303 anti-GPC3 antibody-drug conjugate | – | Phase 1 | Hepatocellular Carcinoma | Dec 2027 |
| CRT-402 CD19-targeted CAR-T cell therapy designed to deplete CD19-positive B cells | CD19 | Phase 1 | Autoimmune Diseases | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07334119 | MT-304 | Phase 1 | HER2-Expressing Solid Tumors | Oncology | Jan 2027 |
| NCT05969041 | MT-302 | Phase 1 | Epithelial Tumors, Malignant | Oncology | Aug 2027 |
| NCT06478693 | MT-303 | Phase 1 | Hepatocellular Carcinoma | Oncology | Dec 2027 |
| NCT07778446 | CRT-402 | Phase 1 | Autoimmune Diseases | Immunology | Dec 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.